Distribution Alliance for Infectious Disease Tests

By Labmedica staff writers
Posted on 03 Aug 2004

An agreement has been announced that grants DakoCytomation (Glostrup, Denmark) co-exclusive rights to market and sell the infectious disease diagnostic tests based on the nucleic acid detection of LightUp Technologies AB (Huddinge, Sweden).

The parties will work jointly to achieve a strong market penetration and to develop more products based on LightUp's ReSSQ assay technology and DakoCytomation's knowledge of markets and customer contacts. LightUp is a company developing and commercializing innovative technologies for the fast-growing molecular diagnostic segment of the in vitro diagnostics industry. The company's ReSSQ assays provide simpler and more accurate identification and quantification of disease-generating organisms. The LightUp Probe at the heart of the method is designed to work with real-time polymerase chain reaction (PCR) and can be used in many medical applications.

DakoCytomation is a leading cancer diagnostics company in the field of personalized medicine. The company provides systems solutions for clinical laboratories and life science research. Its tests and instruments allow doctors to link diagnostic results to specific therapies and optimize patient care.

Related Links:
LightUp Technologies
DakoCytomation